Oncosec Medical (NASDAQ:ONCS) Could Burn Your Long Portfolio After More Shorts

February 17, 2018 - By Louis Casey

 Oncosec Medical (NASDAQ:ONCS) Could Burn Your Long Portfolio After More Shorts

The stock of Oncosec Medical (NASDAQ:ONCS) registered an increase of 1.83% in short interest. ONCS’s total short interest was 1.84 million shares in February as published by FINRA. Its up 1.83% from 1.81 million shares, reported previously. With 1.09M shares average volume, it will take short sellers 2 days to cover their ONCS’s short positions. The short interest to Oncosec Medical’s float is 9.73%.

The stock decreased 6.94% or $0.14 during the last trading session, reaching $1.81. About 1.29 million shares traded or 39.90% up from the average. OncoSec Medical Incorporated (NASDAQ:ONCS) has declined 34.57% since February 17, 2017 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $77.72 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) earned “Buy” rating by H.C. Wainwright on Friday, December 15. The rating was maintained by H.C. Wainwright on Friday, January 19 with “Buy”. The firm earned “Buy” rating on Wednesday, March 9 by H.C. Wainwright. Maxim Group maintained OncoSec Medical Incorporated (NASDAQ:ONCS) on Thursday, June 8 with “Buy” rating. Maxim Group maintained OncoSec Medical Incorporated (NASDAQ:ONCS) on Friday, June 2 with “Buy” rating. H.C. Wainwright maintained OncoSec Medical Incorporated (NASDAQ:ONCS) rating on Thursday, November 9. H.C. Wainwright has “Buy” rating and $6.0 target. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) earned “Buy” rating by Rodman & Renshaw on Thursday, July 21. Noble Financial maintained the stock with “Buy” rating in Tuesday, June 13 report. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. H.C. Wainwright maintained the shares of ONCS in report on Friday, June 2 with “Buy” rating.

More notable recent OncoSec Medical Incorporated (NASDAQ:ONCS) news were published by: Prnewswire.com which released: “OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next …” on November 07, 2017, also Marketwatch.com with their article: “OncoSec Medical Inc.” published on May 10, 2017, Prnewswire.com published: “OncoSec Receives $9.3 Million Warrant Exercise” on November 13, 2017. More interesting news about OncoSec Medical Incorporated (NASDAQ:ONCS) were released by: Prnewswire.com and their article: “OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock” published on January 31, 2018 as well as Prnewswire.com‘s news article titled: “This Morning’s Technical Outlook on Biotech Stocks — NewLink Genetics, OHR …” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.